Atopic Dermatitis Learning Hub

Welcome to the AD learning hub focused on key scientific education on atopic dermatitis, featuring ADVENT resources.

Atopic dermatitis (AD) is a chronic, relapsing, systemic disease with a high impact on the lives of patients and caregivers that requires early intervention and long-term disease control. View resources below to learn more about a variety of topics related to AD.

Early Intervention & Disease Modification in AD

Discover the potential benefits of early intervention in atopic dermatitis and learn how disease modification can support sustained remission and reduce the progression of comorbidities.

IL-4 Contributes to Systemic Type 2 Inflammation in AD
Dermatology
expert video

IL-4 Contributes to Systemic Type 2 Inflammation in AD

Atopic Dermatitis Events of Interest

Atopic Dermatitis Events of Interest highlight congresses and latest educational opportunities relating to understanding the science of Atopic Dermatitis.

EADV 2025
Congress

ADVENT at EADV 2025

Join leading dermatologists for educational symposia on atopic dermatitis, bullous pemphigoid, and chronic spontaneous urticaria at the EADV congress in Paris, France.

Related events

Congress

ADVENT at EADV 2025

Congress

ADVENT in Orlando, 2025

Congress

ADVENT at San Diego, 2024

Congress

ADVENT at EADV 2024

Test your knowledge

Check your understanding of the latest clinical insights and disease management.
Dermatology
MD, MA

Katrina Abuabara

Dermatology
ANP-BC, DCNP, FAANP, MSN

Lakshi Aldredge

Dermatology
MD, PhD

Paolo Amerio

Dermatology
MD, MPH

April Armstrong

Dermatology
MD

Matthias Augustin

Dermatology
MD

Christine Bangert

Dermatology
MD, PhD

Eulàlia Baselga

Dermatology
MD

Pedro Bastos

Dermatology
MD

Lisa Beck

Dermatology
MD

Anna Belloni Fortina

Allergy/Immunology
MD, MSc

Moshe Ben-Shoshan

Dermatology
MD, PhD, MDRA

Thomas Bieber

MAT-GLB-2504165 - 1.0 - 10/2025

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region